Together is a new resource for anyone affected by pediatric cancer - patients and their parents, family members, and friends.Learn More
Often used for:
Treatment of cytokine release syndrome (CRS); juvenile arthritis; rheumatoid arthritis
Tocilizumab is used to treat severe cytokine release syndrome (CRS) during CAR T-cell immunotherapy. This drug blocks a protein called interleukin-6 (IL-6) and acts to decrease the body’s immune response (immunosuppressant) and lower cytokine production.
Patients will have regular blood draws to check blood counts and monitor kidney and liver function. Blood pressure, heart rate, breathing, and temperature may be monitored to watch for infusion-related side effects.
This drug may increase the risk of infection, especially in patients with a weak immune system. Patients may be tested for tuberculosis (TB) and hepatitis B before starting treatment.
May be given as a liquid into a vein by IV
May be given as a liquid under the skin (subcutaneous)
Not all patients who take tocilizumab will experience these side effects. Common side effects are bolded, but there may be others. Please report all suspected side effects to your doctor or pharmacist.
Some patients may experience long-term or late effects of treatment that may continue or develop months or years after treatment ends. Possible late effects due to tocilizumab include:
Be sure to discuss these and other recommendations with your doctor or pharmacist.
Also see: Tisagenlecleucel